FY2025 EPS Estimates for SLDB Decreased by Cantor Fitzgerald

Solid Biosciences Inc. (NASDAQ:SLDB) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a report issued on Tuesday, November 4th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($1.96) per share for the year, down from their previous estimate of ($1.86). Cantor Fitzgerald has a “Overweight” rating and a $16.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for Solid Biosciences’ FY2026 earnings at ($2.03) EPS.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Monday, November 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06).

Several other analysts also recently issued reports on the company. Wedbush decreased their price target on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, August 13th. Citigroup decreased their target price on Solid Biosciences from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday. Wall Street Zen downgraded Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Barclays set a $9.00 price target on Solid Biosciences and gave the company an “overweight” rating in a report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.70.

Solid Biosciences Price Performance

Shares of NASDAQ SLDB opened at $3.93 on Thursday. The business’s 50-day moving average price is $5.62 and its two-hundred day moving average price is $5.05. Solid Biosciences has a one year low of $2.41 and a one year high of $7.37. The company has a market capitalization of $306.03 million, a P/E ratio of -1.58 and a beta of 2.75.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Legal & General Group Plc boosted its position in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after purchasing an additional 4,534 shares during the last quarter. CWM LLC boosted its position in shares of Solid Biosciences by 15,188.5% in the 1st quarter. CWM LLC now owns 7,950 shares of the company’s stock worth $29,000 after purchasing an additional 7,898 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Solid Biosciences in the 2nd quarter worth $54,000. Finally, Ground Swell Capital LLC bought a new position in shares of Solid Biosciences in the 1st quarter worth $42,000. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.